Anti-Type S APL (PML/RARA) Rabbit Polyclonal Antibody for WB, ELISA - P29590/P10276

Core Product Specifications and Parameters

Biological Background: PML Function and Localization

• PML acts as the scaffold protein of PML nuclear bodies (PML-NBs) implicated in tumor suppression, transcriptional regulation, apoptosis, senescence, DNA damage response, and viral defense. It inhibits EIF4E-mediated mRNA nuclear export by reducing EIF4E affinity for the 5' m7G cap of target mRNAs. Related references: PMID:11500381 PMID:11575918 PMID:18391071
• Isoform PML-4 crucially regulates apoptosis and growth suppression: activates RB1, inhibits AKT1 via phosphatases, negatively modulates the PI3K pathway (inhibiting MTOR, activating PTEN), and positively regulates p53 by promoting acetylation/phosphorylation and blocking MDM2-mediated degradation.
• PML-4 functions as a transcriptional repressor of TBX2 during cellular senescence, requires a functional RBL2/E2F4 complex, regulates DNA double-strand break repair via WRN interaction, negatively controls telomerase by binding TERT, and modulates PER2 nuclear localization and circadian rhythm.
• Nuclear isoforms (PML-1 to PML-5) cooperate with SATB1 in local chromatin-loop remodeling and gene expression regulation at the MHC-I locus; PML-2 is required for efficient IFN-gamma-induced MHC II gene transcription via CIITA regulation.
• PML exhibits broad antiviral activity against DNA and RNA viruses through diverse isoform-specific mechanisms, including sequestration of virion capsids, inhibition of viral mRNA/protein synthesis, and SUMO-dependent restriction of viral polymerases.
• Functions as an E3 SUMO-protein ligase, with isoforms PML-3 and PML-6 displaying the highest SUMOylation activity; sumoylates viral and cellular targets, such as HHV-5 immediate early protein IE1. Related references: PMID:20972456 PMID:28250117
• Subcellularly, PML localizes to the nucleus (nucleoplasm, PML bodies, nucleolus), cytoplasm, endoplasmic reticulum membrane, and early endosome membrane; PML-NBs are disrupted in acute promyelocytic leukemia by the PML-RARA oncoprotein.
• PML belongs to the TRIM protein family (TRIM19), contains RING finger, B-box, and coiled-coil domains; alternative splicing yields multiple isoforms with distinct biological functions and subcellular distributions.

Experimental Guidance and Technical Tips

• The immunogen mix of C-terminal PML and N-terminal RARA peptides is designed to target the PML/RARA fusion junction; consider that reactivity with wild-type PML or RARA is possible and should be validated using fusion-positive versus -negative cell models.
• For Western blotting, multiple bands may appear due to PML isoforms (~47–50 kDa) and RARA variants (~62–97 kDa); the PML-RARA fusion protein may migrate differently, so use appropriate APL-positive controls (e.g., NB4 cell line).
• ELISA can be employed for screening or titration; recombinant PML-RARA protein or cell lysates from APL patient samples can serve as positive controls.
• As a polyclonal antibody, it may offer robust detection but requires careful blocking and antibody dilution optimization to minimize nonspecific background.
• The product is shipped on ice bag; upon receipt, store at the recommended temperature to maintain long-term stability.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio provides comprehensive IVD raw-material sourcing services, including validated antibodies and recombinant proteins tailored for hematological malignancy research. From bulk polyclonal antibodies like this anti-PML/RARA to customized monoclonal pairs and ancillary reagents, we support procurement from concept to clinic. Whether you need rare-target raw materials or assay development consultation, CamelBio bridges your sourcing needs with reliable supply solutions.